Status
Conditions
Treatments
About
Evaluate the effectiveness and safety of Limosilactobacillus fermentum LF61 as a food supplement compared to a placebo in improving intestinal and immune functions in healthy adults.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
40 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Xu Fei, Doctor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal